Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:11:19.008Z.
Calculation as of: 2026-10-06T19:11:19.008Z.
Quote observation: 2026-10-06T19:05:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$7.74M
PS Ratio
N/A
TTM Avg
1162916.20
3Y Avg
640325.60
5Y Avg
640325.60
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.89M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.91M | N/A | 33.16 | 27.80 | 27.84 |
| Traws Pharma, Inc. (TRAW)vs › | $7.90M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.74M | N/A | 1162916.20 | 640325.60 | 640325.60 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.79M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.15M | N/A | 851.62 | 851.62 | 851.62 |
| DataMEDS AI, Inc. (MEDS)vs › | $8.28M | 1.03 | 0.68 | 1.19 | 1.19 |
| HeartSciences Inc. (HSCS)vs › | $8.17M | N/A | 795.02 | 643.34 | 689.54 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.47M | 23.70 | 20.17 | 15.94 | 138.16 |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.38M | 0.33 | 0.20 | 0.21 | 0.26 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
